Prime Medicine (PRME) Competitors $2.89 +0.02 (+0.70%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends PRME vs. TVTX, VIR, SDGR, XNCR, ARDX, NRIX, KNSA, RCUS, OCUL, and MRVIShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include Travere Therapeutics (TVTX), Vir Biotechnology (VIR), Schrödinger (SDGR), Xencor (XNCR), Ardelyx (ARDX), Nurix Therapeutics (NRIX), Kiniksa Pharmaceuticals (KNSA), Arcus Biosciences (RCUS), Ocular Therapeutix (OCUL), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry. Prime Medicine vs. Travere Therapeutics Vir Biotechnology Schrödinger Xencor Ardelyx Nurix Therapeutics Kiniksa Pharmaceuticals Arcus Biosciences Ocular Therapeutix Maravai LifeSciences Prime Medicine (NYSE:PRME) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation. Which has more risk and volatility, PRME or TVTX? Prime Medicine has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Which has higher valuation and earnings, PRME or TVTX? Travere Therapeutics has higher revenue and earnings than Prime Medicine. Travere Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime MedicineN/AN/A-$198.13M-$2.05-1.41Travere Therapeutics$203.45M7.05-$111.40M-$4.55-4.04 Is PRME or TVTX more profitable? Prime Medicine has a net margin of 0.00% compared to Travere Therapeutics' net margin of -172.75%. Prime Medicine's return on equity of -107.87% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Prime MedicineN/A -107.87% -74.97% Travere Therapeutics -172.75%-537.74%-55.65% Does the MarketBeat Community prefer PRME or TVTX? Travere Therapeutics received 57 more outperform votes than Prime Medicine when rated by MarketBeat users. However, 62.86% of users gave Prime Medicine an outperform vote while only 57.66% of users gave Travere Therapeutics an outperform vote. CompanyUnderperformOutperformPrime MedicineOutperform Votes2262.86% Underperform Votes1337.14% Travere TherapeuticsOutperform Votes7957.66% Underperform Votes5842.34% Does the media refer more to PRME or TVTX? In the previous week, Travere Therapeutics had 10 more articles in the media than Prime Medicine. MarketBeat recorded 13 mentions for Travere Therapeutics and 3 mentions for Prime Medicine. Travere Therapeutics' average media sentiment score of 0.65 beat Prime Medicine's score of 0.40 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Travere Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of PRME or TVTX? 70.4% of Prime Medicine shares are owned by institutional investors. 23.5% of Prime Medicine shares are owned by company insiders. Comparatively, 3.8% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate PRME or TVTX? Prime Medicine currently has a consensus price target of $13.13, indicating a potential upside of 354.15%. Travere Therapeutics has a consensus price target of $24.00, indicating a potential upside of 30.65%. Given Prime Medicine's stronger consensus rating and higher probable upside, equities analysts plainly believe Prime Medicine is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Travere Therapeutics 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92 SummaryPrime Medicine beats Travere Therapeutics on 11 of the 18 factors compared between the two stocks. Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$379.05M$2.96B$5.36B$19.88BDividend YieldN/A1.94%5.13%3.70%P/E Ratio-1.4145.5689.4741.44Price / SalesN/A358.911,253.3217.17Price / CashN/A192.9043.7519.84Price / Book2.113.975.325.73Net Income-$198.13M-$41.02M$122.60M$993.95M7 Day Performance-1.70%8.62%0.87%3.21%1 Month Performance9.47%10.70%4.80%5.20%1 Year Performance-54.77%5.54%27.90%19.33% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine3.8305 of 5 stars$2.89+0.7%$13.13+354.2%-57.5%$379.05MN/A-1.41234Analyst UpgradeTVTXTravere Therapeutics2.8542 of 5 stars$18.47+2.1%$23.67+28.1%+99.0%$1.44B$203.45M-4.06460Analyst ForecastAnalyst RevisionVIRVir Biotechnology4.1793 of 5 stars$10.46-13.6%$34.83+233.0%+0.8%$1.44B$62.04M-2.67580Analyst RevisionSDGRSchrödinger1.8738 of 5 stars$19.22-0.4%$32.90+71.2%-28.7%$1.40B$193.35M-8.21790XNCRXencor4.2139 of 5 stars$19.87-3.6%$36.56+84.0%-3.8%$1.39B$85.16M-6.21280Positive NewsARDXArdelyx3.7438 of 5 stars$5.78+14.0%$9.25+60.0%-41.2%$1.37B$251.85M-19.2790Analyst ForecastNRIXNurix Therapeutics2.3195 of 5 stars$18.97+4.0%$30.35+60.0%+127.6%$1.34B$56.42M-6.52300KNSAKiniksa Pharmaceuticals2.8928 of 5 stars$18.07-9.3%$36.60+102.5%-1.7%$1.30B$384.10M-129.06220Insider TradeAnalyst RevisionNews CoverageGap DownRCUSArcus Biosciences1.8814 of 5 stars$13.82-2.7%$34.00+146.0%-17.7%$1.26B$263M-4.39500OCULOcular Therapeutix3.6584 of 5 stars$8.02-2.3%$16.71+108.4%+93.0%$1.26B$61.44M-6.08267News CoverageGap DownMRVIMaravai LifeSciences4.6431 of 5 stars$4.95+2.1%$10.28+107.7%-23.3%$1.25B$276.92M-3.02610 Related Companies and Tools Related Companies Travere Therapeutics Alternatives Vir Biotechnology Alternatives Schrödinger Alternatives Xencor Alternatives Ardelyx Alternatives Nurix Therapeutics Alternatives Kiniksa Pharmaceuticals Alternatives Arcus Biosciences Alternatives Ocular Therapeutix Alternatives Maravai LifeSciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:PRME) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRME Stock Alerts